Showing 821-830 of 9295 results for "".
Scientifically Speaking: Correcting and Avoiding Complications in Dark Skin Tones, Part 2 of 2
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-correcting-and-avoiding-complications-in-dark-skin-tones-part-2-of-2/19898/Advancements in energy-based devices mean that these tools can be used across a range of skin tones. But complications can and do still occur. In part two of a discussion on EBDs used in darker skin types, host Joel L. Cohen, MD reviews cases with Michelle Henry, MD, Omar Ibrahimi, MD, PhD, and JennAssessing the Role of Phototherapy in Psoriasis
https://practicaldermatology.com/topics/psoriasis/assessing-the-role-of-phototherapy-in-psoriasis/19887/Despite therapeutic advancements, phototherapy remains a beneficial treatment for many psoriasis patients. Henry Lim, MD summarizes his presentation from San Diego Dermatology Symposium, emphasizing safety and COVID-19 protocols.Ask an Expert: What's the Role for Infliximab in HS?
https://practicaldermatology.com/topics/general-topics/ask-an-expert-whats-the-role-for-infliximab-in-hs/19671/Evidence shows that infliximab, with its weight-based dosing, can be effective for hidradenitis suppurative. Steven Cohen, MD discusses the data and practical considerations with host Adam Friedman, MD.Food and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/food-and-atopic-dermatitis/19644/Many patients believe certain foods can exacerbate AD. Peter Lio, MD discusses the potential link.The Risk of Violence Against Physicians
https://practicaldermatology.com/topics/practice-management/the-risk-of-violence-against-physicians/19641/Violence against healthcare workers is a real and growing risk. Kathleen J. Hectorne, MD outlines the problem and ways to de-escalate an encounter.Cash Savings Alternative: Increase Returns & Maintain Liquidity
https://practicaldermatology.com/topics/practice-management/cash-savings-alternative-increase-returns-maintain-liquidity--wnhimepo/18366/OJM Group Director of Financial Advisors Michael Lewellen, CFP provides an overview and financial example of a cash savings alternative that offers 100% liquidity while providing a higher return than traditional investment vehicles. Click here to request or download a free copy of Wealth ProtectionAesthetics: A European Perspective
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetics-a-european-perspective/18581/When it comes to cosmetic interventions, philosophies of beauty are similar are both sides of the Atlantic. But the tools to achieve aesthetic improvement are different. Dr. Sabine Zenker discusses what's different in Europe, including the availability of injection systems.Best Practices: Allan Wirtzer, MD on Leadership
https://practicaldermatology.com/topics/practice-management/best-practices-allan-wirtzer-md-on-leadership/18592/Sometimes the most important role of a physician is leader. Whether in your practice or for your specialty overall, doctors must lead the charge forward. In this edition of Best Practices, host Joel L. Cohen, MD talks to Allan S. Wirtzer, MD about issues affecting medicine, including coding, and theRobert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDrug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.